Tag Archives: Exelixis

July, 2018

May, 2018

January, 2018

December, 2017

October, 2017

August, 2017

March, 2017

October, 2016

  • 10 October

    Exelixis’ Kidney Cancer Drug Beats Pfizer’s Sutent in Mid-Stage Study

    SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Oct. 10, 2016– Exelixis, Inc.(NASDAQ:EXEL) today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Principal investigator Toni …

September, 2016